Physician profile
Meagan C Chavarria
NPI 1467843086
$21,395.36
in general payments reported to CMS, 2019-2025
31 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $909 · 2023: $1,556 · 2024: $6,523 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,991 · Food and Beverage: $5,433 · Consulting Fee: $4,574 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,410 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,991.11 |
| Food and Beverage | $5,432.57 |
| Consulting Fee | $4,573.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,410.00 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $7,875.80 | 2025 | Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,847.31 | 2024-2025 | Ofev, Jascayd |
| Actelion Pharmaceuticals US, INC. | $3,617.90 | 2022-2025 | Uptravi, Opsumit |
| United Therapeutics Corporation | $1,158.66 | 2022-2025 | Tyvaso, Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $675.35 | 2023-2025 | |
| Grifols USA, LLC | $487.19 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Baxter Healthcare | $483.14 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Abbvie INC. | $263.31 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $228.52 | 2022-2025 | Tezspire |
| Astellas Pharma US INC | $217.43 | 2022-2025 | Cresemba |
| Regeneron Healthcare Solutions, INC. | $184.29 | 2023-2025 | Dupixent |
| Edwards Lifesciences Corporation | $180.95 | 2022 | |
| Insmed, INC. | $177.20 | 2023-2025 | Arikayce |
| Johnson & Johnson Health Care Systems INC. | $172.13 | 2023-2025 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $146.99 | 2024-2025 | Aralast, Glassia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $122.63 | 2022-2023 | Treprostinil |
| Abbott Laboratories | $119.84 | 2022 | |
| Ani Pharmaceuticals, INC. | $76.76 | 2024-2025 | Purified Cortrophin Gel |
| Shionogi INC | $48.71 | 2024-2025 | Fetroja |
| Mallinckrodt Hospital Products INC. | $46.96 | 2023-2024 | Acthar |
| Pfizer INC. | $44.37 | 2023-2024 | |
| Pharming Healthcare, INC. | $37.40 | 2023-2024 | Ruconest |
| Viatris Specialty LLC | $32.71 | 2025 | Yupelri |
| Glaxosmithkline, LLC. | $25.81 | 2024 | Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $20.80 | 2023 | |
| Jazz Pharmaceuticals INC. | $18.74 | 2024 | |
| Liquidia Technologies, INC. | $18.54 | 2025 | Yutrepia |
| Alexion Pharmaceuticals, INC. | $17.32 | 2024 | Ultomiris |
| Caris Mpi, INC. | $16.88 | 2025 | Mi Cancer Seek |
| Inogen, INC. | $16.41 | 2025 | |
| Boston Scientific Corporation | $15.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meagan Chavarria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.